addition of bevacizumab to up-front therapy for egfr nsclc
Published 7 years ago • 313 plays • Length 5:02Download video MP4
Download video MP3
Similar videos
-
8:04
refining use of egfr tkis, adding bevacizumab
-
5:47
egfr tkis for upfront treatment of nsclc
-
3:29
bevacizumab in egfr-mutant nsclc
-
16:30
up-front treatment in egfr wild-type patients
-
5:39
use of bevacizumab for lung cancer
-
2:38
combining bevacizumab with egfr tkis in lung cancer
-
7:48
should avastin be added to egfr tki therapy for egfr mutation-positive nsclc?
-
4:39
treatment for egfr nsclc
-
4:02
bevacizumab in nonsquamous nsclc
-
8:48
upfront use of immunotherapy for ncslc
-
9:26
adding avastin to tarceva help egfr positive lung cancer patients?
-
6:41
egfr-positive nsclc: treatment at progression
-
5:15
metastatic nsclc: a look at the impower150 trial
-
8:28
upfront egfr-targeted therapy
-
1:56
dr. haigentz on the potential of erlotinib and bevacizumab in egfr-mutant nsclc
-
7:40
bevacizumab in nonsquamous lung cancer
-
1:31
impower150: efficacy outcomes of atezolizumab addition in pre-treated egfr-mutated nsclc
-
1:33
real-world experience of impower150 regimen for egfr nsclc
-
7:09
treatment of metastatic egfr-positive nsclc